(GMAB) Genmab A/S BCG Matrix Research

Teprotumumab is the first approved therapy for thyroid eye disease, and that first-mover edge keeps it the market leader in a niche specialty field. Tepezza generated about $1.9 billion in 2025 sales, showing strong demand despite a limited patient pool. With thyroid eye disease affecting roughly 50,000 to 100,000 people in the U.S. and diagnosis still improving, the franchise can keep growing as treatment access expands.

• First approved thyroid eye disease therapy
• 2025 sales: about $1.9 billion
• Strong first-mover brand visibility
• Growth tied to higher diagnosis rates

Tisotumab vedotin is a Star for Genmab A/S: it is approved for recurrent or metastatic cervical cancer, a high-unmet-need solid tumor with about 661,000 new cases and 348,000 deaths worldwide in 2022. Growth still depends on broader uptake and label expansion, but the niche is real and clinically hard to serve.

• Approved for recurrent/metastatic cervical cancer
• Targets a high-unmet-need niche
• Upside depends on uptake and expansion

Ofatumumab CLL is a legacy anti-CD20 asset that dates back to its 2009 FDA approval, and it now sits far behind newer growth drivers. Genmab’s Kesimpta franchise has become the clear royalty engine, while the CLL version acts more like a harvest asset than a growth story. That makes this Cash Cow useful for steady cash, but not for meaningful top-line expansion.

• 2009 approval; now a mature brand.
• Growth lags Kesimpta by a wide margin.
• Supports cash flow, not expansion.

Genmab A/S still leans on partnered antibody economics: FY2025 cash came mainly from royalties and milestones tied to external programs, so it can turn drug wins into income without heavy selling spend. That fits a BCG Cash Cow profile: mature, low-growth, and cash-generative rather than capital-hungry.

• Royalties convert partner sales into cash.
• Milestones need limited promotion spend.
• Core value comes from mature antibody deals.

Lu AF82422 in Phase 2 for multiple system atrophy is a high-risk "question mark" in Genmab A/S's BCG Matrix. The program has zero market share today, no approved MSA therapy, and approval still depends on a long, uncertain clinical path. If it works, the upside is large; in 2025/2026, the revenue contribution is still 0.

• Phase 2 only
• MSA unmet need is severe
• Market share is zero
• Growth is still hypothetical

JNJ-64007957 (teclistamab) and JNJ-64407564 (talquetamab) sit in a crowded multiple myeloma field with CAR-Ts, antibody-drug conjugates, and other bispecifics already launched. J&J has already pushed both into a mature, highly competitive class, so Genmab’s visible share is limited and the upside looks low relative to the number of rivals.

In BCG terms, that mix of low certainty and weak share fits Dogs. The class is crowded, switching costs are high, and leadership is already set by larger franchises with broader sales reach.

• High competition in multiple myeloma
• Low visible share for Genmab
• Limited BCG growth fit

DuoBody-CD40x4-1BB is a Genmab solid-tumor immune agonist in a crowded, fast-growing oncology niche. Its addressable market is large, but Genmab has no commercial share here yet, so it fits a Question Mark in BCG terms.

If clinical data turn strong, the asset could matter a lot; if not, it stays a cash sink. The global oncology market was about $225 billion in 2024 and keeps expanding, which supports the upside case.

• High-growth segment
• Zero current revenue share
• Big upside, high risk

HexaBody-CD38 and DuoHexaBody-CD37 stay Question Marks because they are still in clinical development, but both target malignant blood cancers, a field that makes up about 10% of new global cancer cases. Genmab A/S already has deep hematology know-how, so these assets fit its core science and could matter if efficacy turns into approvals.

Until late-stage data and regulatory wins arrive, they remain high-potential, high-risk bets.

• Core hematology fit
• Approval risk still high